Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 244

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 244
---
 or sell additional shares outside
of a Rule 10b5-1 plan when they are not in possession of material nonpublic information subject to compliance with the terms of our insider trading policy. Prior to 180 days after the date of this offering, subject to early termination, the sale of
any shares under such plans would be prohibited by the lock-up agreement that the director or officer has entered into with the underwriters.

178

EXECUTIVE COMPENSATION The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. As an emerging growth company, we have opted to comply with the executive compensation disclosure rules applicable to “smaller reporting companies,” as such term is defined in the rules promulgated under the Exchange Act. The compensation provided to our named executive officers (“NEOs”) for the fiscal years ended December 31, 2024 and December 31, 2023 is detailed in the 2024 Summary Compensation Table and accompanying footnotes and narrative that follow. Our named executive officers for the fiscal year ended December 31, 2024, which consist of our Chief Executive Officer and the next two most highly compensated executive officers (other than our Chief Executive Officer) who were serving as our executive officers on December 31, 2024, are:

| • |     | Michael Cloonan, M.B.A., our President and Chief Executive Officer; |

| • |     | Elena Ridloff, C.F.A., our Chief Financial Officer and Head of Corporate Development; and |

| • |     | Charlotte McKee, M.D., our Chief Medical Officer. |

Compensation Philosophy Our executive compensation philosophy is to provide a competitive and market-based total compensation program to attract, motivate, and retain our executive team. Our compensation is based heavily on performance, which aligns with our goal to drive long-term growth and value creation. 2024 Summary Compensation Table The following table sets forth information regarding compensation awarded to, earned by or paid to our NEOs for services rendered to us in all capacities during the fiscal years ended December 31, 2023 and December 31, 2024.

| Name and principal position   |     | Year |      |     | Salary ($) |         |     | Option 
 Awards 
 ($)(1) |           |     | Non-Equ